13 Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
Amgen Inc. (AMGN) is seeing ratings go up from a C last week to a B this week. Amgen Inc. discovers, develops, manufactures, and markets medicines for serious illnesses. The company also gets A’s in earnings growth and return on equity. For more information, get Portfolio Grader’s complete analysis of AMGN stock.
This week, Gilead Sciences, Inc. (GILD) pushes up from a C to a B rating. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The company also gets A’s in sales growth, earnings growth, earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of GILD stock.
The rating of Ophthotech Corp. (OPHT) moves up this week, rising from a C to a B. For more information, get Portfolio Grader’s complete analysis of OPHT stock.
Portola Pharmaceuticals, Inc. (PTLA) improves from a B to a A rating this week. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of PTLA stock.
Acceleron Pharma Inc (XLRN) earns a B this week, jumping up from last week’s grade of C. For more information, get Portfolio Grader’s complete analysis of XLRN stock.
ACADIA Pharmaceuticals Inc. (ACAD) shows solid improvement this week. The company’s rating rises from a C to a B. ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of ACAD stock.
This week, Repligen Corporation’s (RGEN) ratings are up from a B last week to a A. Repligen Corporation is a biopharmaceutical company that develops therapeutics for radiology and neuropsychiatry. The company also gets A’s in sales growth, earnings growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of RGEN stock.
This is a strong week for Akebia Therapeutics, Inc. (AKBA). The company’s rating climbs to B from the previous week’s C. The company also gets A’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of AKBA stock.
Ohr Pharmaceutical Inc (OHRP) gets a higher grade this week, advancing from a C last week to a B. Ohr Pharmaceutical Inc develops pharmaceuticals for wound care and to treat cachexia. The company also gets A’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of OHRP stock.
BioTime, Inc.’s (BTX) ratings are looking better this week, moving up to a B from last week’s C. BioTime, Inc. is a biotechnology company that focuses on regenerative medicine and blood plasma volume expanders. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of BTX stock.
MediciNova, Inc. (MNOV) boosts its rating from a C to a B this week. MediciNova, Inc. acquires, develops, and commercializes small molecule therapeutics. The company also gets A’s in earnings revisions and earnings momentum. For more information, get Portfolio Grader’s complete analysis of MNOV stock.
This week, CytRx Corporation (CYTR) pushes up from a C to a B rating. CytRx Corporation is a biopharmaceutical research and development company that specializes in oncology. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of CYTR stock.
Sophiris Bio Inc. (SPHS) is seeing ratings go up from a B last week to a A this week. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of SPHS stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
